Are Analysts Bearish Medifast, Inc. (NYSE:MED) After Last Week?

June 26, 2018 - By Migdalia James

Medifast, Inc. (NYSE:MED) LogoInvestors sentiment decreased to 1.28 in Q1 2018. Its down 0.05, from 1.33 in 2017Q4. It is negative, as 17 investors sold Medifast, Inc. shares while 63 reduced holdings. 52 funds opened positions while 50 raised stakes. 10.03 million shares or 1.93% less from 10.23 million shares in 2017Q4 were reported.
Element Cap Ltd Liability has invested 0.01% in Medifast, Inc. (NYSE:MED). Invesco invested in 92,910 shares. State Of Tennessee Treasury Department invested 0% of its portfolio in Medifast, Inc. (NYSE:MED). Vanguard Grp Inc owns 825,822 shares. Bridgeway Cap Mngmt holds 0.01% or 5,000 shares. Atlantic Tru Limited Company holds 0% or 500 shares. Aqr Capital Management Ltd Liability Com has invested 0% of its portfolio in Medifast, Inc. (NYSE:MED). The New Jersey-based Landscape Capital Mngmt Limited Liability Com has invested 0.18% in Medifast, Inc. (NYSE:MED). Rice Hall James And Ltd Liability Company invested 0.2% in Medifast, Inc. (NYSE:MED). The Illinois-based Chicago Equity Prtnrs Ltd Liability Com has invested 0.04% in Medifast, Inc. (NYSE:MED). Renaissance Tech Ltd Liability Company holds 992,600 shares or 0.1% of its portfolio. Parkside National Bank And Tru owns 6 shares. The Massachusetts-based Bogle Mgmt Lp De has invested 0.43% in Medifast, Inc. (NYSE:MED). Los Angeles Equity Incorporated invested in 31,113 shares. Bancorp Of Ny Mellon accumulated 175,792 shares or 0% of the stock.

Since March 8, 2018, it had 0 insider buys, and 3 sales for $4.87 million activity. Another trade for 40,000 shares valued at $3.47M was made by MACDONALD MICHAEL C on Thursday, March 8.

Medifast, Inc. (NYSE:MED) Ratings Coverage

Among 2 analysts covering Medifast (NYSE:MED), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Medifast had 2 analyst reports since April 19, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, May 24 by DA Davidson. As per Thursday, April 19, the company rating was downgraded by Sidoti. Below is a list of Medifast, Inc. (NYSE:MED) latest ratings and price target changes.

24/05/2018 Broker: DA Davidson Old Rating: Buy New Rating: Buy Old Target: $135 New Target: $161 Maintain
19/04/2018 Broker: Sidoti Old Rating: Buy New Rating: Neutral Downgrade

The stock decreased 0.40% or $0.62 during the last trading session, reaching $154.19. About 236,789 shares traded or 16.61% up from the average. Medifast, Inc. (NYSE:MED) has risen 238.34% since June 26, 2017 and is uptrending. It has outperformed by 225.77% the S&P500.

Medifast, Inc., through its subsidiaries, produces, distributes, and sells weight loss, weight management, healthy living products, and other consumable health and diet products. The company has market cap of $1.86 billion. The firm offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, eggs, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape For Life, Flavors of Home, and Essential 1 brands, as well as Dual Fuel, a sports nutrition pilot program. It has a 55.27 P/E ratio. It also provides meal replacements comprising vitamins and minerals; and hydration products, as well as other nutrients for health purposes.

More recent Medifast, Inc. (NYSE:MED) news were published by: which released: “6 Defensive Stocks to Buy as Trade Tensions Flare Up” on June 19, 2018. Also published the news titled: “Medifast, Inc. Announces Quarterly Dividend” on June 14, 2018.‘s news article titled: “Dow Set For Another Loss; Amazon Falls on SCOTUS Ruling” with publication date: June 21, 2018 was also an interesting one.

Medifast, Inc. (NYSE:MED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.